Session 10: Novel Therapies for CLL I: Non-Immunological Approaches

Co-Chair(s)

• 

  Jennifer Woyach, MD

  Professor of Medicine
  Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center
  Columbus, Ohio, United States
• FB

  Francesc Bosch, MD, PhD

  Head, Dept of Hematology; Director, Experimental Hematology (VHIO); Professor
  Universtitat Autonoma Barcelona, Hospital Universitari Vall d'Hebron
  Barcelona, Catalonia, Spain

Presentations:

• 08:15 - 08:30 CEST

  The Emerging Promise of Targeted Protein Degraders
  

  Speaker: Alexey V. Danilov, MD, PhD – Department of Hematology and Transplantation, City of Hope National Medical Center
• 08:30 - 08:45 CEST

  Novel BCR Pathway Targeting Agents
  

  Speaker: Deborah M. Stephens, DO – Lineberger Comprehensive Cancer Center, University of North Carolina
• 08:45 - 09:00 CEST

  Targeting Surface Antigens
  

  Speaker: Kerry A. Rogers, MD – Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center
• 09:00 - 09:15 CEST

  Novel Approaches with Anti-Apoptotic Therapy
  

  Speaker: Jacob Soumerai, MD – Center for Lymphoma, Massachusetts General Hospital Cancer Center, Harvard Medical School
• 09:15 - 09:30 CEST

  Panel Discussion With Interactivity and Audience Q&A
• 09:30 - 09:35 CEST

  Targeting SF3B1 Disrupts Chronic Lymphocytic Leukemia Survival via PFKFB-mediated Glycolytic Dependency
  

  Primary Author: Yongyi Yuan, MS – Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital

  Co-Author / Presenter: Hao Guo, MD, PhD – Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
• 09:35 - 09:40 CEST

  Targeting BTKi-Resistant CLL Using the Dual Irreversible/Reversible 4th Generation BTK Inhibitor Rocbrutinib
  

  Primary Author / Presenter: Britten K. Gordon, BS – The Ohio State University